Anzemet

Anzemet is a brand name of dolasetron, approved by the FDA in the following formulation(s):

ANZEMET (dolasetron mesylate - injectable; injection)

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: September 11, 1997
  
  Strength(s): 100MG/5ML (20MG/ML) ^[RLD], 12.5MG/0.625ML (20MG/ML) ^[RLD]


• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: December 11, 2001
  
  Strength(s): 500MG/25ML (20MG/ML) ^[RLD]

ANZEMET (dolasetron mesylate - tablet; oral)

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: September 11, 1997
  
  Strength(s): 100MG ^[RLD], 50MG
  

Has a generic version of Anzemet been approved?

No. There is currently no therapeutically equivalent version of Anzemet available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Anzemet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
  Patent 4,906,755
  Issued: March 6, 1990
  Inventor(s): Gittos; Maurice W.
  Assignee(s): Merrell Dow Pharmaceuticals Inc.
  The present invention is directed to a group of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(3H)-ones and related compounds. The compounds are prepared from the appropriate carboxylic acids and alcohols by standard procedures or, where steric factors are significant, a new process which makes use of heavy metal salts of super acids can be used. The compounds involved are useful in the treatment of migraine and similar disorders and in cytotoxic drug-induced vomiting.
  
  Patent expiration dates:
  
  
  • July 2, 2011
    
  
  

See also...

• Anzemet Consumer Information (Drugs.com)
• Anzemet Consumer Information (Wolters Kluwer)
• Anzemet Tablets Consumer Information (Wolters Kluwer)
• Anzemet Consumer Information (Cerner Multum)
• Anzemet Advanced Consumer Information (Micromedex)
• Anzemet AHFS DI Monographs (ASHP)
• Dolasetron Consumer Information (Wolters Kluwer)
• Dolasetron Tablets Consumer Information (Wolters Kluwer)
• Dolasetron Consumer Information (Cerner Multum)
• Dolasetron injection Consumer Information (Cerner Multum)
• Dolasetron Oral, Intravenous Advanced Consumer Information (Micromedex)
• Dolasetron Mesylate AHFS DI Monographs (ASHP)